Dong Shuangshan

Dr. Dong Shuangshan

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2022 in Antioxidants
Verified
Journal Article
Open access
PDF file
SXSun Xiao
Sun Xiao
DSDong Shuangshan
Dong Shuangshan
HKHiroki Kato
Hiroki Kato
JKJun Kong
Jun Kong
YIYosuke Ito
Yosuke Ito
KMKeiji Masuda
Keiji Masuda
Mitochondrial fission factor (MFF) is an adapter that targets dynamin-related protein 1 from the cytosol to the mitochondria for fission. Loss-of-function MFF mutations cause encephalopathy due to defective mitochondrial and peroxisomal fission 2 (EMPF2). To elucidate the molecular mechanisms that were involved, we analyzed the functional effects of MFF depletion in deciduous teeth-derived dental pulp stem cells differentiating into dopaminergic neurons (DNs). When treated with MFF-targeting small interfering RNA, DNs showed impaired neurite outgrowth and reduced mitochondrial signals in neurites harboring elongated mitochondria. MFF silencing also caused mitochondrial Ca2+ accumulation through accelerated Ca2+ influx from the endoplasmic reticulum (ER) via the inositol 1,4,5-trisphosphate receptor. Mitochondrial Ca2+ overload led DNs to produce excessive reactive oxygen species (ROS), and downregulated peroxisome proliferator-activated receptor-gamma co-activator-1 alpha (PGC-1α). MFF was co-immunoprecipitated with voltage-dependent anion channel 1, an essential component of the ER-mitochondrial Ca2+ transport system. Folic acid supplementation normalized ROS levels, PGC-1α mediated mitochondrial biogenesis, and neurite outgrowth in MFF depleted DNs, without affecting their mitochondrial morphology or Ca2+ levels. We propose that MFF negatively regulates the mitochondrial Ca2+ influx from the ER. MFF-insufficiency recapitulated the EMPF2 neuropathology with increased oxidative stress and suppressed mitochondrial biogenesis. ROS and mitochondrial biogenesis might be potential therapeutic targets for EMPF2.

19 September 2023 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Open access
DSDong Shuangshan
Dong Shuangshan
TKTakashi Kifune
Takashi Kifune
HKHiroki Kato
Hiroki Kato
LWLu Wang
Lu Wang
JKJun Kong
Jun Kong
KMKeiji Masuda
Keiji Masuda
Melatonin entrainment of suprachiasmatic nucleus-regulating circadian rhythms is mediated by MT1 and MT2 receptors. Melatonin also has neuroprotective and mitochondrial activating effects, suggesting it may affect neurodevelopment. We studied melatonin's pharmacological effects on autism spectrum disorder (ASD) neuropathology. Deciduous tooth-derived stem cells from children with ASD were used to model neurodevelopmental defects and differentiated into dopaminergic neurons (ASD-DNs) with or without melatonin. Without melatonin, ASD-DNs had reduced neurite outgrowth, mitochondrial dysfunction, lower mitochondrial Ca2+ levels, and Ca2+ accumulation in the endoplasmic reticulum (ER) compared to control DNs from typically developing children-derived stem cells. Melatonin enhanced IP3-dependent Ca2+ release from ER to mitochondria, improving mitochondrial function and neurite outgrowth in ASD-DNs. Luzindole, an MT1/MT2 antagonist, blocked these effects. Thus, melatonin supplementation may improve dopaminergic system development in ASD by modulating mitochondrial Ca2+ homeostasis via MT1/MT2 receptors.

16 February 2026 in The FASEB Journal
Verified
Journal Article
Open access
DSDong Shuangshan
Dong Shuangshan
LWLu Wang
Lu Wang
HKHiroki Kato
Hiroki Kato
SHSaki Hirofuji
Saki Hirofuji
ZZZhiyan Zhou
Zhiyan Zhou
KMKeiji Masuda
Keiji Masuda
Rett syndrome (RTT) is a rare neurodevelopmental disorder caused by loss‐of‐function mutations in the gene encoding methyl‐CpG‐binding protein 2 (MECP2) that is located on the X chromosome. Affected individuals also exhibit a variety of non‐neurological symptoms such as kyphoscoliosis and osteoporosis. Thus, MECP2 may play a functional role in bone remodeling and osteoblast differentiation. This study aimed to clarify the molecular mechanisms underlying the deregulation of bone remodeling in RTT. Human deciduous tooth‐derived mesenchymal stem cells that exhibit osteoblast plasticity were used as a cellular model of RTT. Using a small interfering RNA‐mediated MECP2 (MECP2‐siR) knockdown system, we quantitatively analyzed the RUNX2‐dependent and canonical Wnt signaling pathways during osteoblast differentiation. Expression of active β‐catenin, RUNX2, and their downstream targets (osteocalcin and alkaline phosphatase) and mineralization were decreased in MECP2‐siR‐treated osteoblasts compared to that in control osteoblasts. In contrast, the MECP2‐siR‐treated osteoblasts exhibited an increase in the endogenous Wnt antagonist DKK1. Notably, MECP2/DKK1 double‐knockdown osteoblasts possessed greater β‐catenin and RUNX2 levels than MECP2 single‐knockdown osteoblasts. Furthermore, microRNA126‐3p was upregulated in MECP2‐siR‐treated osteoblasts, and an antagomir of microRNA126‐3p prevented DKK1 upregulation, thereby improving the levels of active β‐catenin and other osteoblastic phenotypes. These results suggest that MECP2 insufficiency enhances DKK1 expression via the upregulation of microRNA126‐3p, suppressing the canonical Wnt signaling and subsequent RUNX2‐dependent osteoblast differentiation. The present study provides insights into the molecular mechanisms involved in impaired osteoblast differentiation that contribute to the development of osteoporosis in RTT.

10 September 2026 in International Dental Journal
Verified
Journal Article
Open access
DSDong Shuangshan
Dong Shuangshan
ZSZiyan Sun
Ziyan Sun
JSJiajian Shang
Jiajian Shang
HLHuina Liu
Huina Liu
ZFZhipeng Fan
Zhipeng Fan
Functional tooth regeneration remains a major challenge in clinical dentistry and depends on the precise odontogenic/osteogenic commitment of resident stem cells. Micro-peptides encoded by long noncoding RNAs represent a novel source of bioactive molecules for regenerative therapy. This study aimed to investigate whether a newly identified 76-amino acid micro-peptide, PLXDC2-OT-peptide, promotes odontogenic/osteogenic differentiation of stem cells from the apical papilla (SCAPs) and to clarify its underlying mechanism. The biological effects of PLXDC2-OT-peptide were evaluated in SCAPs using in vitro assays for biocompatibility, cell migration, mineralisation and odontogenic/osteogenic marker expression. Three-dimensional organoid culture was used to assess matrix maturation, and an in vivo model was established to examine dentin-like tissue formation over 12 weeks. RNA sequencing and bioinformatic enrichment analyses were performed to identify peptide-regulated genes and signalling pathways. Mechanistic validation was conducted to determine the involvement of the PI3K-AKT signalling pathway. PLXDC2-OT-peptide showed favourable biocompatibility and significantly enhanced SCAP migration, mineralised nodule formation and the expression of odontogenic/osteogenic markers, including DSPP, DMP1, RUNX2 and OCN. The peptide also promoted extracellular matrix maturation in 3D organoids and induced dentin-like tissue formation in vivo. Transcriptomic analysis identified 330 upregulated and 338 downregulated genes following peptide treatment. Enrichment analyses revealed marked changes in growth factor binding and cell cycle-related pathways, with PI3K-AKT signalling emerging as a key pathway. Mechanistic experiments confirmed that PLXDC2-OT-peptide promoted odontogenic/osteogenic differentiation of SCAPs through activation of the PI3K-AKT signalling pathway. PLXDC2-OT-peptide is a novel lncRNA-encoded micro-peptide that enhances odontogenic/osteogenic differentiation of SCAPs and promotes dentin-like tissue regeneration, at least partly through PI3K-AKT signalling activation. PLXDC2-OT-peptide may serve as a promising synthetic therapeutic candidate for dental defect repair and regenerative endodontic applications.